They are being developed for the treatment of cancers in which PI3K/AKT pathway activation may be relevant for tumor growth or therapeutic resistance, and have demonstrated PI3K/AKT pathway inhibition in preclinical studies.[7,8] By synthesizing data from multiple clinical trials, we aimed to provide a comprehensive overview of current evidence regarding the use of AKT inhibitors in TNBC treatment. The gene discussed is AKT1; the disease is cancer.